Major Sjögren’s Syndrome (pSS) has been characterised as a hypersensitivity response sort II systemic autoimmune persistent illness inflicting exocrine gland dysfunction primarily affecting girls close to the menopausal age. pSS sufferers exhibit dryness of the principle mucosal surfaces and are extremely susceptible to lymphoma improvement. This paper presents a primary biomedical ontology for pSS based mostly on a reference mannequin which was decided by pSS scientific specialists.
The following ontology constitutes the elemental foundation for mapping pSS-related ontologies from worldwide cohorts to a typical ontology. The ontology mapping (i.e., schematic interlinking) process is, in reality, a preliminary step to harmonize heterogeneous medical knowledge obtained from numerous cohorts.
Freedom and the psychoanalytic ontology of quantum physics.
Jung’s paper ‘Synchronicity – an acausal connecting precept’, defining the phenomenon as a ‘significant’ coincidence relying on archetypal activation, was revealed in 1952, along with a conceptually associated piece by physicist and Nobel Laureate Wolfgang Pauli entitled, ‘The affect of archetypal concepts on the scientific theories of Kepler’. Slavoj Žižek, in The Indivisible The rest: On Schelling and Associated Issues, means that, in distinction to any notion of a ‘pre-modern Jungian concord’, the principle lesson of quantum physics was that not solely was the psychoanalytic, empty topic of the signifier constitutively out-of-joint with respect to the world, however that the Actual in itself was already incomplete, out-of-joint, ‘not-all’.
But whereas Žižek ceaselessly tries to separate Jung from his personal ontology, this paper reveals that his ontology will not be as totally different as he suggests. In step with our earlier publications on Jung and Zizek, a better investigation reveals an underlying congruence of each of their approaches. On this paper we present that this affinity lies within the rejection by each Jung and Žižek of the ideology of reductive materialism, a rejection that demonstrably attracts on quantum physics in related methods. Whereas Jung posits an inherently significant universe, Žižek makes an attempt to salvage the liberty of human subjectivity by opposing his Lacanian ‘dialectical materialism’ to reductive materialism.
Ontology-based systematic illustration and evaluation of conventional Chinese language medication towards rheumatism.
Rheumatism represents any illness situation marked with irritation and ache within the joints, muscle tissues, or connective tissues. Many conventional Chinese language medication have been used for a very long time to deal with rheumatism. Nonetheless, a complete data supply for these medication continues to be lacking, and their anti-rheumatism mechanisms stay unclear. An ontology for anti-rheumatism conventional Chinese language medication would strongly assist the illustration, evaluation, and understanding of those medication.
On this research, we first systematically collected reported details about 26 conventional Chinese language decoction items medication, together with their chemical components and adversarial occasions (AEs). By largely reusing phrases from current ontologies (e.g., TCMDPO for conventional Chinese language medicines, NCBITaxon for taxonomy, ChEBI for chemical parts, and OAE for adversarial occasions) and making semantic axioms linking totally different entities, we developed the Ontology of Chinese language Medication for Rheumatism (OCMR) that features over 3000 class phrases.
|
Recombinant Humanp21 Recombinant Protein |
|
ProSci |
|
TWEAK, recombinant / TNFSF12, recombinant (Human) |
|
PHOENIX PEPTIDE |
|
TAGLN Recombinant Protein (Rat) (Recombinant- Tag) |
|
ABM |
|
TAGLN2 Recombinant Protein (Rat) (Recombinant Tag) |
|
ABM |
|
TAGLN3 Recombinant Protein (Rat) (Recombinant Tag) |
|
ABM |
Our OCMR evaluation discovered that these 26 conventional Chinese language decoction items are made out of anatomic entities (e.g., root and stem) from three Bilateria animals and 23 Mesangiospermae vegetation. Anti-inflammatory and antineoplastic roles are essential for anti-rheumatism medication. Utilizing the entire of 555 distinctive ChEBI chemical entities recognized from these medication, our ChEBI-based classification evaluation recognized 18 anti-inflammatory, 33 antineoplastic chemical substances, and 9 chemical substances (together with three diterpenoids and three triterpenoids) having each anti-inflammatory and antineoplastic roles.
Moreover, our research detected 22 diterpenoids and 23 triterpenoids, together with 16 pentacyclic triterpenoids which might be seemingly bioactive towards rheumatism. Six medication have been discovered to be related to 184 distinctive AEs, together with three AEs (i.e., dizziness, nausea and vomiting, and anorexia) every related to 5 medication. A number of chemical entities are labeled as neurotoxins (e.g., diethyl phthalate) and allergens (e.g., eugenol), which can clarify the formation of some TCD AEs. The OCMR might be effectively queried for helpful data utilizing SPARQL scripts.
The OCMR ontology was developed to systematically symbolize 26 conventional anti-rheumatism Chinese language medication and their associated data. The OCMR evaluation recognized attainable anti-rheumatism and AE mechanisms of those medication. Our novel ontology-based strategy can be utilized to systematic illustration and evaluation of different conventional Chinese language medication.
|
Recombinant Humanp21 Recombinant Protein |
|
92-035 |
|
TWEAK, recombinant / TNFSF12, recombinant (Human) |
|
054-85 |
|
TAGLN Recombinant Protein (Rat) (Recombinant- Tag) |
|
RP232205 |
|
TAGLN2 Recombinant Protein (Rat) (Recombinant Tag) |
|
RP232208 |
|
TAGLN3 Recombinant Protein (Rat) (Recombinant Tag) |
|
RP232211 |
Quick and Correct Metadata Authoring Utilizing Ontology-Primarily based Suggestions.
In biomedicine, high-quality metadata are essential for locating experimental datasets, for understanding how experiments have been carried out, and for reproducing these experiments. Regardless of the current deal with metadata, the standard of metadata accessible in public repositories continues to be extraordinarily poor. A key issue is that the standard metadata acquisition course of is time-consuming and error susceptible, with weak or nonexistent assist for linking metadata to ontologies.
There’s a urgent want for strategies and instruments to hurry up the metadata acquisition course of and to extend the standard of metadata which might be entered. On this paper, we describe a technique and set of related instruments that we developed to deal with this problem.
 RCN1 Antibody |
|
CSB-PA877399XA01OFG-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Oryza sativa subsp. japonica (Rice) RCN1 protein |
RCN1 Antibody |
|
CSB-PA330526XA01SVG-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) RCN1 protein |
RCN1 Antibody |
|
CSB-PA330526XA01SVG-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) RCN1 protein |
 RCN1/2 Antibody |
|
PHY4455S |
PhytoAB |
150 μg |
EUR 289 |
 RCN1 Polyclonal Antibody |
|
27480 |
SAB |
100ul |
EUR 439 |
RCN1 Polyclonal Antibody |
|
27480-100ul |
SAB |
100ul |
EUR 302.4 |
RCN1 Polyclonal Antibody |
|
27480-50ul |
SAB |
50ul |
EUR 224.4 |
 RCN1 polyclonal antibody |
|
BS78220 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
RCN1 polyclonal antibody |
|
BS71546 |
Bioworld Biotech |
50 ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
RCN1 Polyclonal Antibody |
|
E-AB-92398-120uL |
Elabscience Biotech |
120uL |
EUR 320 |
|
|
|
Description: Unconjugated |
RCN1 Polyclonal Antibody |
|
E-AB-92398-200uL |
Elabscience Biotech |
200uL |
EUR 530 |
|
|
|
Description: Unconjugated |
RCN1 Polyclonal Antibody |
|
E-AB-92398-60uL |
Elabscience Biotech |
60uL |
EUR 200 |
|
|
|
Description: Unconjugated |
RCN1 Polyclonal Antibody |
|
E-AB-92398-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
RCN1 Polyclonal Antibody |
|
MBS2547735-006mL |
MyBiosource |
0.06mL |
EUR 180 |
RCN1 Polyclonal Antibody |
|
MBS2547735-012mL |
MyBiosource |
0.12mL |
EUR 255 |
RCN1 Polyclonal Antibody |
|
MBS2547735-02mL |
MyBiosource |
0.2mL |
EUR 400 |
RCN1 Polyclonal Antibody |
|
MBS2547735-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1715 |
RCN1 Polyclonal Antibody |
|
MBS9131061-002mL |
MyBiosource |
0.02mL |
EUR 200 |
RCN1 Polyclonal Antibody |
|
MBS9131061-005mL |
MyBiosource |
0.05mL |
EUR 255 |
RCN1 Polyclonal Antibody |
|
MBS9131061-01mL |
MyBiosource |
0.1mL |
EUR 345 |
RCN1 Polyclonal Antibody |
|
MBS9131061-02mL |
MyBiosource |
0.2mL |
EUR 545 |
RCN1 Polyclonal Antibody |
|
MBS9131061-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
RCN1 Polyclonal Antibody |
|
MBS9431356-005mL |
MyBiosource |
0.05mL |
EUR 300 |
RCN1 Polyclonal Antibody |
|
MBS9431356-01mL |
MyBiosource |
0.1mL |
EUR 390 |
RCN1 Polyclonal Antibody |
|
MBS9431356-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1610 |
) RCN1 Antibody (C-term) |
|
MBS9202637-008mL |
MyBiosource |
0.08mL |
EUR 210 |
RCN1 Antibody (C-term) |
|
MBS9202637-04mL |
MyBiosource |
0.4mL |
EUR 430 |
RCN1 Antibody (C-term) |
|
MBS9202637-5x04mL |
MyBiosource |
5x0.4mL |
EUR 1910 |
 Antibody) Reticulocalbin 1 (RCN1) Antibody |
|
abx126465-100l |
Abbexa |
100 µl |
EUR 175 |
Reticulocalbin 1 (RCN1) Antibody |
|
20-abx126465 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ul
- 50 ul
- 100 ul
- 200 ul
|
|
|
Reticulocalbin 1 (RCN1) Antibody |
|
abx126465-1ml |
Abbexa |
1 ml |
EUR 387.5 |
Reticulocalbin 1 (RCN1) Antibody |
|
abx126465-200l |
Abbexa |
200 µl |
EUR 275 |
 RCN1 Rabbit Polyclonal Antibody |
|
JOT-AP04418-100ul |
Jotbody |
100ul |
EUR 220 |
RCN1 Rabbit Polyclonal Antibody |
|
JOT-AP04418-50ul |
Jotbody |
50ul |
EUR 144 |
 RCN1 antibody - C-terminal region |
|
MBS3216389-01mL |
MyBiosource |
0.1mL |
EUR 455 |
RCN1 antibody - C-terminal region |
|
MBS3216389-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1995 |
 RCN1 Polyclonal Conjugated Antibody |
|
C27480 |
SAB |
100ul |
EUR 476.4 |
RCN1 Polyclonal Conjugated Antibody |
|
MBS9439371-01mLAF350 |
MyBiosource |
0.1mL(AF350) |
EUR 480 |
RCN1 Polyclonal Conjugated Antibody |
|
MBS9439371-01mLAF405 |
MyBiosource |
0.1mL(AF405) |
EUR 480 |
RCN1 Polyclonal Conjugated Antibody |
|
MBS9439371-01mLAF488 |
MyBiosource |
0.1mL(AF488) |
EUR 480 |
RCN1 Polyclonal Conjugated Antibody |
|
MBS9439371-01mLAF555 |
MyBiosource |
0.1mL(AF555) |
EUR 480 |
RCN1 Polyclonal Conjugated Antibody |
|
MBS9439371-01mLBiotin |
MyBiosource |
0.1mL(Biotin) |
EUR 480 |
 Rabbit Monoclonal Antibody) RCN1 (5R9) Rabbit Monoclonal Antibody |
|
E28M3718 |
EnoGene |
100ul |
EUR 295 |
 Blocking Peptide) RCN1 Antibody (C-term) Blocking Peptide |
|
MBS9221973-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 ARP64355_P050-25UL - RCN1 Antibody - C-terminal region |
|
ARP64355_P050-25UL |
Aviva Systems Biology |
25ul |
EUR 99 |
|
|
) ARP64355_P050 - RCN1 antibody - C-terminal region (ARP64355_P050) |
|
ARP64355_P050 |
Aviva Systems Biology |
100ul |
EUR 389 |
|
|
 RCN1 |
|
CSB-CL618980HU |
Cusabio |
10 μg plasmid + 200μl Glycerol |
Ask for price |
RCN1 |
|
MBS8535412-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
RCN1 |
|
MBS8535412-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
RCN1 |
|
MBS8535412-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
RCN1 |
|
MBS8535412-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
RCN1 |
|
pro-544 |
ProSpec Tany |
2µg |
EUR 60 |
|
Description: Recombinant Human Reticulocalbin 1 |
) RCN1, CT (RCN1, RCN, Reticulocalbin-1) |
|
MBS642883-02mL |
MyBiosource |
0.2mL |
EUR 695 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) |
|
MBS642883-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
 (AP)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (AP) |
|
MBS6341059-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (AP) |
|
MBS6341059-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (PE)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (PE) |
|
MBS6341069-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (PE) |
|
MBS6341069-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (APC)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (APC) |
|
MBS6341060-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (APC) |
|
MBS6341060-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (FITC)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (FITC) |
|
MBS6341062-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (FITC) |
|
MBS6341062-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (Biotin)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (Biotin) |
|
MBS6341061-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (Biotin) |
|
MBS6341061-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (MaxLight 405)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 405) |
|
MBS6341064-01mL |
MyBiosource |
0.1mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 405) |
|
MBS6341064-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 490)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 490) |
|
MBS6341065-01mL |
MyBiosource |
0.1mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 490) |
|
MBS6341065-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 550)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 550) |
|
MBS6341066-01mL |
MyBiosource |
0.1mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 550) |
|
MBS6341066-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 650)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 650) |
|
MBS6341067-01mL |
MyBiosource |
0.1mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 650) |
|
MBS6341067-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 750)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 750) |
|
MBS6341068-01mL |
MyBiosource |
0.1mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (MaxLight 750) |
|
MBS6341068-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (Azide free) (HRP)) RCN1, CT (RCN1, RCN, Reticulocalbin-1) (Azide free) (HRP) |
|
MBS6341063-02mL |
MyBiosource |
0.2mL |
EUR 980 |
RCN1, CT (RCN1, RCN, Reticulocalbin-1) (Azide free) (HRP) |
|
MBS6341063-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 RCN1 Rabbit pAb |
|
A10572 |
Abclonal |
1000μL |
EUR 623.48 |
RCN1 Rabbit pAb |
|
A10572-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RCN1 Rabbit pAb |
|
A10572-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RCN1 Rabbit pAb |
|
A10572-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RCN1 Rabbit pAb |
|
A10572-50ul |
Abclonal |
50 ul |
EUR 267.6 |
RCN1 Rabbit pAb |
|
A21590 |
Abclonal |
50μL |
EUR 623.48 |
 RCN1 rabbit pAb |
|
E28PN4627 |
EnoGene |
100μl |
EUR 255 |
|
Description: Available in various conjugation types. |
RCN1 Rabbit pAb |
|
E2382702 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
RCN1 Rabbit pAb |
|
E2510571 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
RCN1 rabbit pAb |
|
E44H13511 |
EnoGene |
100ul |
EUR 255 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
RCN1 Rabbit pAb |
|
E45R18187N |
EnoGene |
50 ul |
EUR 297.75 |
 RCN1 cDNA Clone |
|
MBS1272471-001mgPlasmid02mLGlycerolStock |
MyBiosource |
0.01mgPlasmid+0.2mLGlycerol-Stock |
EUR 200 |
RCN1 cDNA Clone |
|
MBS1272471-5x001mgPlasmid5x02mLGlycerolStock |
MyBiosource |
5x0.01mgPlasmid+5x0.2mLGlycerol-Stock |
EUR 855 |
RCN1 Rabbit pAb |
|
MBS8575868-01mL |
MyBiosource |
0.1mL |
EUR 305 |
RCN1 Rabbit pAb |
|
MBS8575868-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
A core element of this strategy is a price advice framework that makes use of evaluation of beforehand entered metadata and ontology-based metadata specs to assist customers quickly and precisely enter their metadata. We carried out an preliminary analysis of this strategy utilizing metadata from a public metadata repository.
